The effectiveness of a weight reduction programme consisting of motivation of the patient, use of an anorectic drug (Tenuate, 25 mg), and diet and exercise was assessed in 110 obese patients in a 12 week, double-blind, placebo-controlled study. The differences in weight loss with continuous therapy (Tenuate) vs placebo and with intermittent therapy (Tenuateplacebo-Tenuate) vs placebo were statistically significant (p = 0·0001 and p = 0·0004 respectively).
No deleterious effects on blood pressure, pulse rate, ECG, and chest x-ray were seen. Only 1 of the original 174 patients dropped out of the study because of side-effects.
Get full access to this article
View all access options for this article.
References
1.
BoileauPA (1968) Control of weight-gain during pregnancy: use of diethylpropion hydrochloride. Applied Therapeutics10, 763
2.
BoldingOT (1974) Diethylpropion hydrochloride: an effective appetite suppressant. Current Therapeutic Research16, 40
3.
le RicheWHCsimaA (1967) A long-acting appetite suppressant drug studied for 24 weeks in both continuous and sequential administration. Canadian Medical Association Journal97, 1016
4.
RosenbergBA (1961) A double-blind study of diethylpropion in obesity. American Journal of Medical Science242, 210
5.
SilverstoneJTCooperRMBeggRR (1970) A comparative trial of fenfluramine and diethylpropion in obesity. British Journal of Clinical Practice24, 423
